Actually, at least one of the historical studies was in children - study 5. From 6 minutes in:
https://www.finnewsnetwork.com.au/P...storEvents_2018/11Oct/RaceOncology/index.html
Also, a jump from 15% to 22% could have a significant impact on Bisantrene efficacy in salvage patients if you assume the extra 7% would have been in the group of those who responded to Bisantrene in the earlier studies.
You must adjust the success rate down accordingly.
Ann: June 2018 Quarterly Report, page-16
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.030(2.10%) |
Mkt cap ! $238.5M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.46 | $1.38 | $123.1K | 87.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19987 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 330 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |